(Q46637665)

23 December 2017

title

Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil (English)

1 reference

23 December 2017

0 references

1 reference

10

1 reference

23 December 2017

author name string

L G Possuelo

1

1 reference

23 December 2017

J A Castelan

2

1 reference

23 December 2017

T C de Brito

3

1 reference

23 December 2017

A W Ribeiro

4

1 reference

23 December 2017

P I Cafrune

5

1 reference

23 December 2017

P D Picon

6

1 reference

23 December 2017

A R Santos

7

1 reference

23 December 2017

R L F Teixeira

8

1 reference

23 December 2017

T S Gregianini

9

1 reference

23 December 2017

M L R Rossetti

11

1 reference

23 December 2017

A Zaha

12

1 reference

23 December 2017

publication date

18 April 2008

1 reference

23 December 2017

European Journal of Clinical Pharmacology

published in

1 reference

23 December 2017

volume

64

1 reference

23 December 2017

page(s)

673-681

1 reference

23 December 2017

issue

7

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1007/s00228-008-0484-8

exact match

0 references

cites work

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00228-008-0484-8

Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin

21 January 2018

1 reference

12 December 2020

The CAGE questionnaire: validation of a new alcoholism screening instrument

1 reference

12 December 2020

Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis

1 reference

12 December 2020

Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population

1 reference

12 December 2020

Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study

1 reference

12 December 2020

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

1 reference

12 December 2020

Clinical Pharmacokinetics of Isoniazid

1 reference

12 December 2020

A simple salting out procedure for extracting DNA from human nucleated cells

1 reference

12 December 2020

Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis

1 reference

12 December 2020

Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification

1 reference

12 December 2020

Allele and genotype frequencies of metabolic genes in Native Americans from Argentina and Paraguay

1 reference

12 December 2020

The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.

1 reference

12 December 2020

Effects of worldwide population subdivision on ALDH2 linkage disequilibrium

1 reference

12 December 2020

Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology.

1 reference

12 December 2020

An E-M algorithm and testing strategy for multiple-locus haplotypes

1 reference

12 December 2020

Isoniazid metabolism in the rabbit, and the effect of rifampin pretreatment

1 reference

12 December 2020

Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis

1 reference

12 December 2020

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

1 reference

12 December 2020

Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites

1 reference

12 December 2020

Pharmacoeconomics of adverse drug reactions

1 reference

12 December 2020

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

1 reference

12 December 2020

Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury

1 reference

12 December 2020

Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy

1 reference

12 December 2020

Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide

1 reference

12 December 2020

NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis

1 reference

12 December 2020

Development of simplified and rapid detection assay for genetic polymorphisms influencing drug response and its clinical applications

1 reference

12 December 2020

HUMAN ACETYLATION POLYMORPHISM

1 reference

12 December 2020

Criteria of drug-induced liver disorders. Report of an international consensus meeting

1 reference

12 December 2020

Genetic profile of the arylamine N-acetyltransferase 2 coding gene among individuals from two different regions of Brazil

1 reference

12 December 2020

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity

1 reference

12 December 2020

Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?

1 reference

12 December 2020

10.1007/S00228-008-0484-8

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

18421452

1 reference

23 December 2017